ArticleOncology letters2021
Identification of prognostic biomarkers associated with metastasis and immune infiltration in osteosarcoma.
Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 34 citations in OpenAlex.
- Metabolic-immune crosstalk in osteosarcoma: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
- Integration of Single-cell Sequencing Analysis Reveals Disulfidptosis Related Molecular Subtype and Novel Prognosis System for Osteosarcoma.Current medicinal chemistry · 2026Article
- Exploring the Tumor Microenvironment in Osteosarcoma: Driver of Resistance and Progression.Cancers · 2025Review
- Article
- Review
- Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights.Frontiers in immunology · 2025Review
- Identification of M2 macrophage markers for predicting outcome and therapeutic response in osteosarcoma: Integrated analysis of single-cell and bulk RNA-sequencing.Journal of Cancer · 2025Article
- Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma.Frontiers in immunology · 2025Review
- [Pathogenesis and potential diagnostic biomarkers of atrial fibrillation in Chinese population: a study based on bioinfor-matics].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Article
- Advances on immunotherapy for osteosarcoma.Molecular cancer · 2024Review
- Osteosarcoma-Associated Immune Genes as Potential Immunotherapy and Prognosis Biomarkers.Biochemical genetics · 2024Article
- EMT-related gene classifications predict the prognosis, immune infiltration, and therapeutic response of osteosarcoma.Frontiers in pharmacology · 2024Article
- Develop a Novel Signature to Predict the Survival and Affect the Immune Microenvironment of Osteosarcoma Patients: Anoikis-Related Genes.Journal of immunology research · 2024Article
- The Prognostic Role of Preoperative Hematological and Inflammatory Indices in Canine Appendicular Osteosarcoma.Veterinary sciences · 2023Article
- Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment.Bone research · 2023Review
- Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.International journal of molecular sciences · 2023Review
- Identification of a novel MYC target gene set signature for predicting the prognosis of osteosarcoma patients.Frontiers in oncology · 2023Article
- Editorial: Advances of innovative therapeutic strategies in age-related diseases.Frontiers in bioengineering and biotechnology · 2023Article
- Bioinformatics analysis of the key genes in osteosarcoma metastasis and immune invasion.Translational pediatrics · 2022Article
- Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common primary malignancy of the bones, and is associated with a high rate of metastasis and a poor prognosis. A tight association between the tumor microenvironment (TME) and osteosarcoma metastasis has been established. In the present study, the Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm was applied to calculate the immune and stromal scores of patients with osteosarcoma based on data from The Cancer Genome Atlas database. A metagene approach and deconvolution method were used to reveal distinct TME landscapes in patients with osteosarcoma. Bioinformatics analysis was used to identify differentially expressed genes (DEGs) associated with metastasis and immune infiltration in osteosarcoma, and a risk model was constructed using the DEGs with potential prognostic significance. Subsequently, gene set enrichment and Spearman's correlation analyses were used to delineate the biological processes associated with these prognostic biomarkers. Finally, immunohistochemical (IHC) analysis was performed to evaluate the expression levels of immune infiltrates and prognostic biomarkers in clinical osteosarcoma tissues. The results of the ESTIMATE demonstrated that patients with non-metastatic osteosarcoma presented with higher immune/stromal scores and a more favorable prognosis compared with those with metastatic osteosarcoma. The TME landscapes in patients with osteosarcoma suggested that high levels of tumor-infiltrating immune cells (TIICs) may suppress metastasis. Increased numbers of CD56
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.